Shu-Xia Li, PhD
Staff Affiliate - YNHHCards
Additional Titles
Associate Director, Data Management & Analytics, Center for Outcomes Research & Evaluation (CORE), Yale School of Medicine
Contact Info
About
Titles
Staff Affiliate - YNHH
Positions outside Yale
Associate Director, Data Management & Analytics, Center for Outcomes Research & Evaluation (CORE), Yale School of Medicine
Biography
Dr. Li is an Associate Director of Date Management and Analytics at Yale-New Haven Hospital Centers for Outcomes Research and Evaluation (CORE). She has help initiated and served in a leadership role in CORE’s big data research project. She has had a dynamic research career with 20+ years of diverse and in-depth hands-on experience in building health care quality measures, designing clinical trials and performing data analysis, pre-clinical data analysis, bio-marker discovery, data mining, genomics, proteomics, gene-expression profiling, and bioinformatics application development in both industrial and academic settings. Her current work focuses on bringing new statistical and mathematical tools in health care outcomes research. She has been collaborating with health care outcome researchers and published in phenotyping hospital drug and procedure variation and utilization patterns, health-care cost/value patterns, risk prediction modeling, and imaging analysis using artificial intelligence. She has also actively engaged in hospital quality measures and surveillance tool development in collaboration with Center for Medicare and Medicaid Service (CMS). She is also interested in precision medicine in the era of big data.
Appointments
Departments & Organizations
Education & Training
- PhD
- Yale University, Biostatistics (2010)
- MS
- Yale Univeristy, Biostatistics (2005)
- PhD
- Ohio University, Molecular and Cellular Biology (1996)
- BS
- Sichuan University, Biology/Genetics (1989)
Research
Overview
Medical Research Interests
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Harlan Krumholz, MD, SM
Kumar Dharmarajan, MD, MBA
Zhenqiu Lin, PhD
Andreas Coppi
Nancy Kim, MD, PhD
Shiwani Mahajan, MBBS, MHS
Treatment Outcome
Quality of Health Care
Publications
2024
Racial and Ethnic Disparities in Age-Specific All-Cause Mortality During the COVID-19 Pandemic
Faust J, Renton B, Bongiovanni T, Chen A, Sheares K, Du C, Essien U, Fuentes-Afflick E, Haywood T, Khera R, King T, Li S, Lin Z, Lu Y, Marshall A, Ndumele C, Opara I, Loarte-Rodriguez T, Sawano M, Taparra K, Taylor H, Watson K, Yancy C, Krumholz H. Racial and Ethnic Disparities in Age-Specific All-Cause Mortality During the COVID-19 Pandemic. JAMA Network Open 2024, 7: e2438918. PMID: 39392630, DOI: 10.1001/jamanetworkopen.2024.38918.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsCOVID-19 public health emergencyNon-HispanicPublic health emergencyOther Pacific IslanderExcess mortalityAlaska NativesUS populationExcess deathsRates of excess mortalityCross-sectional study analyzed dataYears of potential lifeMortality relative riskNon-Hispanic whitesCross-sectional studyPacific IslandersStudy analyzed dataAll-cause mortalityEthnic groupsMortality disparitiesMortality ratioTotal populationDeath certificatesEthnic disparitiesMain OutcomesDecedent ageEffect of the COVID-19 Pandemic on Monitoring and Control of Cardiovascular Risk Factors and Disparities
Lu Y, Brush J, Liu Y, Li S, Asher J, Krumholz H. Effect of the COVID-19 Pandemic on Monitoring and Control of Cardiovascular Risk Factors and Disparities. JACC Advances 2024, 3: 101177. PMID: 39220712, PMCID: PMC11364117, DOI: 10.1016/j.jacadv.2024.101177.Peer-Reviewed Original ResearchConceptsThe PAX LC Trial: A Decentralized, Phase 2, Randomized, Double-blind Study of Nirmatrelvir/Ritonavir Compared with Placebo/Ritonavir for Long COVID
Krumholz H, Sawano M, Bhattacharjee B, Caraballo C, Khera R, Li S, Herrin J, Coppi A, Holub J, Henriquez Y, Johnson M, Goddard T, Rocco E, Hummel A, Al Mouslmani M, Putrino D, Carr K, Carvajal-Gonzalez S, Charnas L, De Jesus M, Ziegler F, Iwasaki A. The PAX LC Trial: A Decentralized, Phase 2, Randomized, Double-blind Study of Nirmatrelvir/Ritonavir Compared with Placebo/Ritonavir for Long COVID. The American Journal Of Medicine 2024 PMID: 38735354, DOI: 10.1016/j.amjmed.2024.04.030.Peer-Reviewed Original ResearchCitationsAltmetricConceptsLC trialPROMIS-29Participants' homesTargeting viral persistencePlacebo-controlled trialDouble-blind studyElectronic health recordsCore Outcome MeasuresLong COVIDEQ-5D-5LRepeated measures analysisEvidence-based treatmentsPhase 2Double-blindParticipant-centred approachStudy drugPrimary endpointSecondary endpointsCommunity-dwellingHealth recordsHealthcare utilizationContiguous US statesViral persistencePatient groupDrug treatmentHypertension Trends and Disparities Over 12 Years in a Large Health System: Leveraging the Electronic Health Records
Brush J, Lu Y, Liu Y, Asher J, Li S, Sawano M, Young P, Schulz W, Anderson M, Burrows J, Krumholz H. Hypertension Trends and Disparities Over 12 Years in a Large Health System: Leveraging the Electronic Health Records. Journal Of The American Heart Association 2024, 13: e033253. PMID: 38686864, PMCID: PMC11179912, DOI: 10.1161/jaha.123.033253.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsElectronic health recordsRegional health systemImprove hypertension careHealth systemHealth recordsHypertension careDiastolic blood pressureAge-adjusted prevalence ratesNon-Hispanic Black patientsPrevalence ratesLarger health systemCross-sectional analysisTransformation of medical dataLeveraging real-world dataHigh prevalence rateHypertension trendsHypertension prevalenceBlood pressureBlood pressure measurementsHypertension diagnosisPrimary outcomeNational trendsProportion of patientsAntihypertensive medicationsBlack patientsPre-COVID-19 hospital quality and hospital response to COVID-19: examining associations between risk-adjusted mortality for patients hospitalised with COVID-19 and pre-COVID-19 hospital quality
Peter D, Li S, Wang Y, Zhang J, Grady J, McDowell K, Norton E, Lin Z, Bernheim S, Venkatesh A, Fleisher L, Schreiber M, Suter L, Triche E. Pre-COVID-19 hospital quality and hospital response to COVID-19: examining associations between risk-adjusted mortality for patients hospitalised with COVID-19 and pre-COVID-19 hospital quality. BMJ Open 2024, 14: e077394. PMID: 38553067, PMCID: PMC10982775, DOI: 10.1136/bmjopen-2023-077394.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsHospital qualityPatient experiencePre-COVID-19Medicare patientsShort-term acute care hospitalsCritical access hospitalsAcute care hospitalsFuture public health emergenciesHigher odds of mortalityIn-hospitalRisk-adjusted mortalityOdds of mortalityCare deliveryAccess hospitalsEffective careCOVID-19-related deathsAssociated with mortalityCare structuresHospital characteristicsPublic health emergencySummary scoreMedicare beneficiariesHigher oddsHospital responseRSMRs
2022
Three-Month Symptom Profiles Among Symptomatic Adults With Positive and Negative Severe Acute Respiratory Syndrome Coronavirus 2 Tests: A Prospective Cohort Study From the INSPIRE Group
Spatz E, Gottlieb M, Wisk L, Anderson J, Chang A, Gentile N, Hill M, Huebinger R, Idris A, Kinsman J, Koo K, Li S, McDonald S, Plumb I, Rodriguez R, Saydah S, Slovis B, Stephens K, Unger E, Wang R, Yu H, Hota B, Elmore J, Weinstein R, Venkatesh A. Three-Month Symptom Profiles Among Symptomatic Adults With Positive and Negative Severe Acute Respiratory Syndrome Coronavirus 2 Tests: A Prospective Cohort Study From the INSPIRE Group. Clinical Infectious Diseases 2022, 76: 1559-1566. PMID: 36573005, PMCID: PMC11361781, DOI: 10.1093/cid/ciac966.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsSARS-CoV-2 symptomsSARS-CoV-2 infectionPost-infectious syndromesProspective cohort studyCohort studyCOVID groupAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSARS-CoV-2 test resultsSyndrome coronavirus 2 infectionEar/nose/throatSevere acute respiratory syndrome coronavirus 2 testsCoronavirus 2 infectionLong-term symptomsNose/throatLong COVIDSymptomatic adultsMean ageActive symptomsSymptom profilesDrug AdministrationSociodemographic characteristicsSymptomsInfectionMonthsUncoupling of all-cause excess mortality from COVID-19 cases in a highly vaccinated state
Faust JS, Renton B, Chen AJ, Du C, Liang C, Li SX, Lin Z, Krumholz HM. Uncoupling of all-cause excess mortality from COVID-19 cases in a highly vaccinated state. The Lancet Infectious Diseases 2022, 22: 1419-1420. PMID: 36007530, PMCID: PMC9395168, DOI: 10.1016/s1473-3099(22)00547-3.Peer-Reviewed Original ResearchCitationsAltmetricMeSH KeywordsSex-Specific Risk Factors Associated With First Acute Myocardial Infarction in Young Adults
Lu Y, Li SX, Liu Y, Rodriguez F, Watson KE, Dreyer RP, Khera R, Murugiah K, D’Onofrio G, Spatz ES, Nasir K, Masoudi FA, Krumholz HM. Sex-Specific Risk Factors Associated With First Acute Myocardial Infarction in Young Adults. JAMA Network Open 2022, 5: e229953. PMID: 35503221, PMCID: PMC9066284, DOI: 10.1001/jamanetworkopen.2022.9953.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsFirst acute myocardial infarctionAcute myocardial infarctionPsychosocial risk factorsRisk factor profilePopulation attributable fractionRisk factor associationsRisk factorsOdds ratioYoung womenAMI subtypesMyocardial infarctionPrevention of AMIType 1 acute myocardial infarctionFactor profileRisk of AMITraditional cardiovascular risk factorsSex-specific risk factorsFactor associationsYoung adultsRisk factor modificationCardiovascular risk factorsStrong associationNutrition Examination SurveyCase-control studyPopulation-based controlsLeading Causes of Death Among Adults Aged 25 to 44 Years by Race and Ethnicity in Texas During the COVID-19 Pandemic, March to December 2020
Faust JS, Chen AJ, Tiako M, Du C, Li SX, Krumholz HM, Barnett ML. Leading Causes of Death Among Adults Aged 25 to 44 Years by Race and Ethnicity in Texas During the COVID-19 Pandemic, March to December 2020. JAMA Internal Medicine 2022, 182: 87-90. PMID: 34807250, PMCID: PMC8609460, DOI: 10.1001/jamainternmed.2021.6734.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and Concepts
2021
Performance Metrics for the Comparative Analysis of Clinical Risk Prediction Models Employing Machine Learning
Huang C, Li SX, Caraballo C, Masoudi FA, Rumsfeld JS, Spertus JA, Normand ST, Mortazavi BJ, Krumholz HM. Performance Metrics for the Comparative Analysis of Clinical Risk Prediction Models Employing Machine Learning. Circulation Cardiovascular Quality And Outcomes 2021, 14: e007526. PMID: 34601947, DOI: 10.1161/circoutcomes.120.007526.Peer-Reviewed Original ResearchCitationsAltmetric
News
News
- July 02, 2024
Yale Faculty Members Named to JACC Editorial Board
- May 28, 2024
Next Generation Research Uses Real-World Data to Identify Most Effective Hypertension Drugs for Patients
- December 18, 2022
Yale Insights in Cardiovascular Medicine: 2022
- May 03, 2022
Surprising Risk Factors May Predict Heart Attacks in Young Women